atezolizumab,talazoparib
roche,pfizer
['atezo', 'talazo', 'biomarker', 'sclc']
lovely phase 2 on maintenance talazoparib in slfn11+ es-sclc having atezo. 79%+ (any staining). n=106 randomized. pfs modestly sign improved but not os. hmmm need to think again on this biomarker. is any slfn+ too loose criterion? #asco23 
Thoracic Oncologist @royalmarsdenNHS, Professor @ICR_London; Chair @BTOGorg; views are my own.